Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4AUT

Crystal structure of the tuberculosis drug target Decaprenyl- Phosphoryl-beta-D-Ribofuranose-2-oxidoreductase (DprE1) from Mycobacterium smegmatis

Summary for 4AUT
Entry DOI10.2210/pdb4aut/pdb
DescriptorDECAPRENYL-PHOSPHORYL-BETA-D-RIBOFURANOSE-2-OXIDOREDUCTASE, FLAVIN-ADENINE DINUCLEOTIDE (3 entities in total)
Functional Keywordsoxidoreductase, tuberculosis, benzothiazinone, mycobacteria
Biological sourceMYCOBACTERIUM SMEGMATIS
Total number of polymer chains1
Total formula weight51976.44
Authors
Primary citationNeres, J.,Pojer, F.,Molteni, E.,Chiarelli, L.R.,Dhar, N.,Boy-Rottger, S.,Buroni, S.,Fullam, E.,Degiacomi, G.,Lucarelli, A.P.,Read, R.J.,Zanoni, G.,Edmondson, D.E.,De Rossi, E.,Pasca, M.R.,Mckinney, J.D.,Dyson, P.J.,Riccardi, G.,Mattevi, A.,Cole, S.T.,Binda, C.
Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium Tuberculosis.
Sci. Transl. Med., 4:121-, 2012
Cited by
PubMed Abstract: The benzothiazinone BTZ043 is a tuberculosis drug candidate with nanomolar whole-cell activity. BTZ043 targets the DprE1 catalytic component of the essential enzyme decaprenylphosphoryl-β-D-ribofuranose-2'-epimerase, thus blocking biosynthesis of arabinans, vital components of mycobacterial cell walls. Crystal structures of DprE1, in its native form and in a complex with BTZ043, reveal formation of a semimercaptal adduct between the drug and an active-site cysteine, as well as contacts to a neighboring catalytic lysine residue. Kinetic studies confirm that BTZ043 is a mechanism-based, covalent inhibitor. This explains the exquisite potency of BTZ043, which, when fluorescently labeled, localizes DprE1 at the poles of growing bacteria. Menaquinone can reoxidize the flavin adenine dinucleotide cofactor in DprE1 and may be the natural electron acceptor for this reaction in the mycobacterium. Our structural and kinetic analysis provides both insight into a critical epimerization reaction and a platform for structure-based design of improved inhibitors.
PubMed: 22956199
DOI: 10.1126/SCITRANSLMED.3004395
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.1 Å)
Structure validation

246905

PDB entries from 2025-12-31

PDB statisticsPDBj update infoContact PDBjnumon